Denali Therapeutics Inc.
DNLIHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Part of the healthcare sector, Denali Therapeutics Inc. (DNLI) is listed under Biotechnology. At a $3.32B market cap, Denali Therapeutics Inc. ranks as a mid-cap company within healthcare. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Market Cap
$3.32B
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-8.45
EPS (TTM)
$-2.88
EPS (Fwd)
$-2.48
ROE
-49.6%
ROA
-27.0%
Cash
$987.7M
Total Debt
$40.0M
Free CF
-$190.3M
52W Change
58.2%
Annual Financials
Cash vs Debt
With $987.7M in cash and $40.0M in debt, DNLI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$190.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -49.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $108.5M (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DNLI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.